Cargando…

Metastatic Pancreatic Cancer: Are We Making Progress in Treatment?

Development of systemic treatment for advanced pancreatic cancer (APC) has been challenging. After fluorouracil, gemcitabine (GEM) became the treatment of choice based on its benefit of symptom relief. Many cytotoxic agents have been combined with GEM in search of regimens with improved survival ben...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiu, Joanne, Yau, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523135/ https://www.ncbi.nlm.nih.gov/pubmed/23304129 http://dx.doi.org/10.1155/2012/898931

Ejemplares similares

Management of adrenocortical carcinoma: are we making progress?
por: Kiesewetter, Barbara, et al.
Publicado: (2021)

Evolution of systemic therapy for advanced HCC patients: Did we make progress in 2022?
por: Wong, Jeffrey Sum Lung, et al.
Publicado: (2023)

An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?
por: Liang, Xu, et al.
Publicado: (2019)

New Treatment Options in Metastatic Pancreatic Cancer
por: Fudalej, Marta, et al.
Publicado: (2023)

Making Diabetes Care Fit—Are We Making Progress?
por: Ruissen, Merel M., et al.
Publicado: (2021)

Pulmonary Protection Strategies in Cardiac Surgery: Are We Making Any Progress?
por: Al Jaaly, Emad, et al.
Publicado: (2015)

Global Blindness: The Progress We Are Making and Still Need to Make
por: Taylor, Hugh R.
Publicado: (2019)

Student progress decision-making in programmatic assessment: can we extrapolate from clinical decision-making and jury decision-making?
por: Tweed, Mike, et al.
Publicado: (2019)

How we treat metastatic colorectal cancer
por: De Falco, Vincenzo, et al.
Publicado: (2020)

Treatment of Pancreatic Cancer: What Can We Really Predict Today?
por: Bachet, Jean-Baptiste, et al.
Publicado: (2011)

Dendritic Cells in Cancer Immunotherapy Clinical Trials: Are We Making Progress?
por: Butterfield, Lisa H.
Publicado: (2013)

Preventing preterm birth: are we making any progress?
por: Kramer, M. S.
Publicado: (1997)

Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going
por: Coppola, Alessandro, et al.
Publicado: (2023)

Metastatic pancreatic cancer: Mechanisms and detection
por: Chen, Xiangling, et al.
Publicado: (2021)

Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
por: Ko, Andrew H
Publicado: (2016)

From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer
por: Martín, Andrés Muñoz, et al.
Publicado: (2018)

Understanding Hyperlactatemia in Human Sepsis: Are We Making Progress?
por: De Backer, Daniel, et al.
Publicado: (2019)

De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?
por: Piombino, Claudia, et al.
Publicado: (2023)

Current understanding of ferroptosis in the progression and treatment of pancreatic cancer
por: Dong, Shi, et al.
Publicado: (2021)

Cancer stem cells: implications for the progression and treatment of metastatic disease
por: Croker, AK, et al.
Publicado: (2008)

Desmoplasia in Pancreatic Cancer. Can We Fight It?
por: Merika, E. E., et al.
Publicado: (2012)

We can make it happen
por: Kallestrup, Per
Publicado: (2017)

Liver transplantation in metastatic colorectal cancer: are we ready for it?
por: Ros, Javier, et al.
Publicado: (2023)

PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?
por: Giraudet, Anne-Laure, et al.
Publicado: (2021)

Massive bleeding in polytrauma: how can we make progress?
por: Vincent, Jean-Louis, et al.
Publicado: (2011)

Reporting of Racial Health Disparities Research: Are We Making Progress?
por: Vince, Randy A., et al.
Publicado: (2022)

Persistent postsurgical pain—How can we make progress?
por: Kehlet, Henrik
Publicado: (2019)

Editorial: Immuno-diagnosis of active tuberculosis; are we making progress?
por: Mayanja-Kizza, Harriet, et al.
Publicado: (2023)

Health Information Systems: how much progress are we making?
por: Reis-Santos, Barbara
Publicado: (2023)

Research Progress in Intestinal Microecology in Pancreatic Cancer Diagnosis and Treatment
por: Han, Zetao, et al.
Publicado: (2022)

Systemic Therapy for Metastatic Pancreatic Cancer
por: Ettrich, Thomas J., et al.
Publicado: (2021)

Making human pancreatic islet organoids: Progresses on the cell origins, biomaterials and three-dimensional technologies
por: Jiang, Lai, et al.
Publicado: (2022)

Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature
por: Oneda, Ester, et al.
Publicado: (2019)

Treatment Options for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma
por: Grzelak, Doreen
Publicado: (2021)

Diagnostic Bioliquid Markers for Pancreatic Cancer: What We Have vs. What We Need
por: Liou, Geou-Yarh, et al.
Publicado: (2023)

Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer
por: Irelli, A., et al.
Publicado: (2014)

Erratum: Editorial: Immuno-diagnosis of active tuberculosis; are we making progress?
Publicado: (2023)

PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?
por: Fusco, Nicola, et al.
Publicado: (2020)

Recent Progress in the Systemic Treatment of Advanced/Metastatic Cholangiocarcinoma
por: Fostea, Raluca Maria, et al.
Publicado: (2020)

Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going
por: Liang, Chen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_282oeq5t8hmtnn94sfk0141mng